Mechanism of action

two routes
metabolism

VYZULTA^TM: One active molecule, two routes^1†

Intraocular pressure (IOP) is a major modifiable risk factor for glaucoma progression
Reduction of IOP reduces risk of glaucomatous visual field loss
VYZULTA^TM is thought to lower IOP by increasing outflow of aqueous humor through both uveoscleral and trabecular meshwork routes^†

VYZULTA^TM is not indicated to reduce the risk of glaucoma progression or glaucomatous visual field loss.

† Clinical significance unknown.

two routes
metabolism

The metabolism of VYZULTA^TM (as studied in animals)^†

After topical ocular administration, VYZULTA^TM is rapidly metabolized in the eye to latanoprost acid, the main active metabolite which is an F2α prostaglandin analogue, and likely butanediol mononitrate. The fate of butanediol mononitrate in ocular tissues is unknown. However, in liver cytosol in vitro, it is reported to be metabolized to
1,4-butanediol and nitric oxide ^†

Adapted from Product Monograph.^1†

^† Clinical significance is unknown.

VYZULTATM: One active molecule, two routes1†

The metabolism of VYZULTATM (as studied in animals)†

VYZULTA^TM: One active molecule, two routes^1†

The metabolism of VYZULTA^TM (as studied in animals)^†